FDA/CDC
News
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
The approval is the second indication for the anti–interleukin-23 monoclonal antibody after clearance for plaque psoriasis was granted in 2019.
FDA/CDC
More than 1 in 10 people in U.S. have diabetes, CDC says
According to the latest National Diabetes Statistics Report, a quarter of those with diabetes are undiagnosed and over a third of the U.S....
FDA/CDC
CDC: More kids hospitalized with COVID since pandemic began
“[It] very well may be that there are just more cases out there, and our children are more vulnerable when they have more cases surrounding them...
FDA/CDC
COVID-19 linked to increased diabetes risk in youth
Two large databases indicate significantly increased diabetes risk among those with COVID-19 but not other acute respiratory illnesses.
FDA/CDC
CDC panel recommends Pfizer COVID-19 boosters for ages 12-15
CDC Director Rochelle Walensky, MD, must still approve the recommendation for it to take effect.
FDA/CDC
New CDC COVID-19 isolation guidelines still up for debate among experts
Sparking the most debate: Infected people are not told to test before leaving isolation.
FDA/CDC
FDA approves first-in-class inclisiran to lower LDL-C
Injectable Inclisiran (Leqvio) is now indicated as an adjunct to maximal statins in adults with cardiovascular disease and patients with...
FDA/CDC
FDA backs Pfizer booster for 12- to 15-year-olds
The agency also shortened the recommended time between a second dose and the booster to 5 months or more,
FDA/CDC
FDA OKs emergency use of Merck pill for COVID-19
Similar to FDA authorization of another antiviral pill regimen granted to Pfizer, molnupiravir should be taken early in the course of COVID-19...
FDA/CDC
FDA approves cabotegravir LA; New HIV PrEP option fills an important gap
“Being able to offer an injectable option is ... a game changer,” said Dr. Lina Rosengren-Hovee of UNC Health.